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Dietary modification such as caloric restriction (CR) has been shown to decrease tumor initiation and progression. We
sought to determine if nutrient restriction could be used as a novel therapeutic intervention to enhance cytotoxic
therapies such as radiation (IR) and alter the molecular profile of triple-negative breast cancer (TNBC), which displays a
poor prognosis. In two murine models of TNBC, significant tumor regression is noted with IR or diet modification, and a
greater regression is observed combining diet modification with IR. Two methods of diet modification were compared,
and it was found that a daily 30% reduction in total calories provided more significant tumor regression than alternate
day feeding. At the molecular level, tumors treated with CR and IR showed less proliferation and more apoptosis. cDNA
array analysis demonstrated the IGF-1R pathway plays a key role in achieving this physiologic response, and multiple
members of the IGF-1R pathway including IGF-1R, IRS, PIK3ca and mTOR were found to be downregulated. The innovative
use of CR as a novel therapeutic option has the potential to change the biology of tumors and enhance the opportunity
for clinical benefit in the treatment of patients with TNBC.

Introduction
Caloric restriction (CR) is an intervention that has been shown
to extend life and reduce age-related and chronic diseases, such
as cardiovascular disease and cancer.1-3 Although the positive
benefits of CR were first described nearly a century ago,4 there
now is renewed interest in CR with an, increasing body of literature demonstrating a direct connection between dietary practices, cancer outcomes and obesity. One such cancer that has
been shown in vivo to respond to CR is breast cancer.5 Caloric
restriction has been shown to not only decrease the incidence, but
also the progression of breast cancers.6,7 Most recently CR has
been shown in vivo to decrease metastases from breast cancer.7
Human epidemiologic studies indicate the relevance of dietary
intake on breast cancer incidence and treatment. Population
studies on obese patients have shown increase rates of breast cancer mortality, while those assessing anorexia nervosa have found

a ~50% decreased risk of breast cancer compared with the normal
population.8
At the molecular level, CR has optimal characteristics to
combat cancer, as it has been shown to increase apoptosis and
decrease the rate of proliferation, angiogenesis, hormones levels and growth factors.9 In fact, many novel therapeutic agents
for cancer treatment are targeted against individual molecules
known to also be targets of CR, such as IGF1-R/Akt pathway,
mTOR and AMP-K.10 These observations have led to investigations into CR as a potential treatment for cancer. To date, CR
has proven to be very important, because it can inhibit mTOR11,12
and can increase the effectiveness of chemotherapy13,14 while protecting normal tissue.12,15,16 Interestingly, many of those same
molecular targets, including mTOR, are also altered with radiation therapy.17-20 Therefore, in this study we sought to determine
if CR could be used in conjunction with radiation therapy to
render cancer cells more susceptible to treatment.
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Figure 1. Experimental design. Tumors were generated by injecting either 67NR or 4T1 cells into the mammary fat pad of balb/c mice. Once tumors
were palpable, mice were treated with IR to the primary tumor alone, treated with a dietary intervention of either ADF or CR or treated with a combination of the two and compared with control mice given no IR and an ad libitum diet.

The use of caloric restriction to augment radiation treatment has not been previously investigated. In this study, an in
vivo model of breast cancer was used to determine if CR could
increase the efficacy of radiation on established tumors. This is
the first study to report the use of CR as a novel therapy in combination with radiation for breast cancer.
Results
Physiologic response of dietary intervention. Dietary caloric
intake has a strong positive correlation for the incidence of
many human cancers,8,21 and spontaneous tumor development in mouse models.22,23 Studies have also shown that large
reductions (40–60% reduction) in caloric intake can slow the
growth of implanted tumors in mouse models.7,24,25 Using an in
vivo model of breast cancer that mimics the clinical presentation in patients, we sought to determine if diet modification
could slow established tumor growth with and without radiation (Fig. 1).
Mice were implanted orthotopically with one of two triplenegative breast cancer (TNBC) cell lines: 4T1, which are highly
metastatic, or 67NR, which are locally aggressive. When palpable tumors formed, feeding changes were instituted; when
tumors reached 100 mm3, radiation was administered, and
tumor growth was recorded.
Mice with both types of TNBC tumors were treated with
one of four conditions: control, which was ad libitum feeding
(AL), alternate day feeing (ADF), IR or ADF + IR. Alternate day
feeding was used, since it has previously been reported to cause a
25–30% reduction in caloric intake over time.17 Measurement of
food intake over the course of the experiment showed an average
intake of 3.71 g per day per mouse for ad libitum fed animals,
whereas ADF mice consumed an average of 6.78 g per fed day
or 3.39 g per day per mouse, about a 9% decrease in caloric
intake. The difference in our observed decrease in intake from
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published reports for ADF may be due to the relatively short
timeline of the experiment (38 d).
ADF did cause a decrease in tumor growth rate when compared with AL controls (Fig. 2A and B) for both 4t1 and 67NR
implants. At 1,000 mm3, ADF caused an average growth delay
of 16% (NS) for 67NR tumors and 30% (p value 1.37E-06) for
4t1 tumors. We also sought to determine how dietary restriction
interacts with ionizing radiation (IR). To determine the proper
dose of radiation to use for each cell line-derived tumor in vitro,
clonogenic expansion assays were performed, and the radiation
dose that achieved 1 log cell kill was determined to be 6 Gy for
67NR cells and 8 Gy for 4t1 cells (Fig. S1). IR alone caused a
delay of 14% (NS) for 67NR tumors and 11% (p value 9.64E-07)
for 4T1 tumors, and ADF combined with IR caused an average growth delay of 25% for 67NR tumors (p-value 0.0069) and
45% for 4T1 tumors (p value 1.32E-07).
Since these results seemed encouraging, but the 20–30%
reduction in calories was not achieved, another cohort of mice
were then treated after palpable 4T1 tumors were generated with
caloric restriction (CR) that constituted controlled daily feeding
of 70% of normal intake, and an additional arm which received
both CR and IR. Compared with AL fed mice at 1,000 mm3, CR
provided a growth delay of 56% (p value 2.29E-06), while the
CR + IR group yielded a more than additive growth delay of 82%
(p value 1.18E-05) (Fig. 2C). All growth delays were considered
significant if p < 0.05 by Student’s t-test.
The weight of each mouse was measured three times a week
for the duration of the experiment and recorded (Figs. 2D–F).
Minor and temporary weight loss was noted with ADF treated
mice that was not observed in AL cohorts (Fig. 2D and E).
Weight loss was observed in CR-treated mice, with an average
weight loss of 12% (Fig. 2F).
Molecular response of dietary interevention. The molecular
changes responsible for the physiologic tumor regression noted
were explored. Histologic evaluation on hematoxylin and eosin
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Figure 2. Tumor re-growth-delay curves for tumors created from two TNBC cell lines: 4T1 and 67NR cells using two different methods of caloric restriction. Mice were treated with each of the following conditions for 67NR (A) cell lines: ad libitum (AL) diet, radiation (RT), alternate day feeding (ADF) or
ADF + RT, and their weights were recorded (B). From the reference of the AL cohort for 67NR tumors at 1,000 mm3, RT gave a 16% growth delay, ADF
14%, ADF + RT 25%. From the reference of the AL cohort for 4T1 and weights were tumors at 1,000 mm3 (C), RT gave a 23% growth delay, ADF 30%,
ADF + RT 45% also recorded for this cohort (D). Using the 4T1 tumors, the ADF method was then compared with a 30% reduction in calories (CR) (E)
using: AL, RT, CR and CR + RT. From the reference of the AL cohort for 4T1 tumors at 1,000 mm3, RT gave a 23% growth delay, CR 56%, CR + RT 82% with
an average weight reduction (F) of 12%. Based on this, the optimal method for performing future studies would be a constant reduction of 30% of the
caloric intake. *Denotes p < 0.05 by Student’s t-test at 1,000 mm3.

for all treatment conditions revealed high-grade tumors with
central necrosis. Tumors were noted to have decreased proliferation with CR alone, IR alone and an even further reduction
with CR + IR when Ki-67 was assessed (Fig. 3A). Apoptosis was
increased with each treatment alone, and when CR was combined with IR, even more apoptosis was noted, as measured with
bcl-2 (Fig. 3B).

www.landesbioscience.com

Evidence demonstrates that caloric restriction provides a benefit in breast cancer by acting on multiple molecular targets, such
as the insulin-like growth factor-1 receptor (IGF-1R) pathway,
inflammatory pathways and estrogen and leptin signaling. To
determine the pathway most important in our triple-negative
breast cancer models, cDNA arrays were done for the 4T1 tumors
exposed to AL, IR, CR and CR + IR. After analyzing by GO-Elite
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stained the ad libitum samples with 3+ intensity and
stained the CR + IR with 1+ intensity.
Mice were euthanized for 2,000 mm3 tumors or for
humane endpoints such as shortness of breath due to
the metastatic tumor burden in the lung. The tumor
regression curves demonstrate that breathing difficulties were reached significantly later in ADF or CR mice
than in AL fed controls, indicating that metastatic
growth is delayed with dietary restriction.
Discussion
Triple-negative breast cancers (TNBC) account for
nearly 20% of breast malignancies and are more aggressive, have poor prognosis and a higher recurrence rate.
Caloric restriction (CR) has been shown to decrease the
incidence and progression of spontaneous breast cancers in murine models and protect normal tissue during chemotherapy. Our results show that a nutritional
intervention represses tumor growth in an additive
manner when combined with radiation in two different aggressive murine models (4T1 and 67NR) of breast
cancer. The average growth delay noted was 15–30%
when treated with ADF alone and greater than 50%
when treated with CR alone. In combination with IR,
a more than additive growth delay was noted at greater
than 80%. The significant increase in growth delay
observed with combination therapy is a promising
result, as it points to CR as a viable adjuvant therapy for
breast cancer patients receiving radiation. Local control
of disease is clearly affected, but it is also intriguing that
the survival of the mice is increased with combination
therapy.
Concern has been raised regarding the use of a
Figure 3. Molecular effects of treatment. Proliferation was evaluated by Ki-67 (A),
dietary intervention with standard cancer therapy.
and bcl-2 was used to evaluate apoptosis (B) for all conditions: Ad lib, CR, IR and
Cancer patients, particularly those with advanced disCR + IR. Combination therapy was noted to decrease proliferation and increase
ease may be at risk of weight loss or cachexia due to
apoptosis in tumors. qRT-PCR of IGF-1R pathway molecules shows downregulation
the molecular properties of advanced disease. In addi(C) with either CR, IR or both. *Notes statistical significance with a p < 0.05.
tion, cancer patients may be on weight-altering chemotherapeutic drugs. In our study, two different regimens
version 1.2.5 (www.genmapp.org/go_elite), we used the GOID of dietary intervention were evaluated including ADF and CR.
system to compare the CR + IR condition with controls; one This demonstrated that mice placed on a regimen of alternate
of the five most significant pathways included the IGF pathway day feeding do not lose weight, while the mice on a CR diet, lost
(Table 1). Since the IGF-1R pathway has been implicated as a an average of 12% (4 g), which was a temporary loss. Similarly,
possible therapeutic target for TNBCs, because its downregula- other published data has not shown irreversible weight loss or
tion leads to apoptosis, this seemed like an appropriate pathway cachexia caused by caloric restriction in cancer models.30 While
to query. In addition, CR 26,27 and IR 28,29 are both independently one human trial examining the effects of caloric restriction in
noted in the literature to decrease members of the pathway.
combination with radiation has just begun, and effects are thereExpression of members of the IGF-1R pathway, including fore unknown, a series by Longo et al. shows that ten patients
IGF-1R, IRS, PIk3ca and mTOR, were evaluated. qRT-PCR were able to undergo short-term fasting during chemotherapy,
reactions showed a reduction in all members assessed (Fig. 3C), and this treatment actually decreased the typical side effects of
which implicates this pathway in mediating the tumor regression the drugs used.15 This effect has also been shown in vitro.12,16
noted. Immunohistochemical evaluation confirmed these results Several other clinical trials testing the effects of ketogenic and
with representative images shown for IGF-1R (Fig. 4B) and low-carbohydrate diets on brain, lung and even cancers known
GSK-3β (Fig. 4C), demonstrating that both of these proteins to be associated with cachexia, including pancreatic cancer and
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Figure 4. Immunohistochemical investigation of proliferation and IGF-1R pathway. Proliferation was also evaluated by immunohistochemistry (IHC)
with Ki-67 staining, which was noted to have higher proliferation in the ad libitum tumors (A) compared with the tumors treated with CR and IR. IGF-1R
was noted to have positive staining (3+) in AL tumors and negative (1+) in CR + IR samples while the downstream target of GSK-3B revealed positive
staining (3+) in AL tumors and 2+ staining in CR + IR tumors.

metastatic cancers, are currently enrolling patients.31,32 Carefully
selecting proper eligibility criteria to enroll patients onto trials
with a dietary intervention will be crucial to their success.

www.landesbioscience.com

At the molecular level, CR has been noted to increase apoptosis while augmenting anti-proliferative effects and decreasing
DNA synthesis.33-36 Our results are congruent with that, and
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Materials and Methods

Table 1. Top 5 GO categories significantly altered with CR and RT combined
GO name

Z score

AVG-log
fold change

STDEV-log
fold change

p
value

Gluconeogenesis

8.385544

1.21299

0.188822

< 0.001

Insulin-like growth
factor binding

8.385544

1.400017

0.182701

< 0.001

Peptide cross-linking

7.797834

1.585857

0.574637

< 0.001

Extracellular region
part

6.449937

1.208581

0.759949

< 0.001

Extracellular region

5.283875

1.287505

0.774612

< 0.001

show that combination therapy with CR and IR cause even more
apoptosis and less proliferation. The ability of CR to slow tumor
growth is likely attributable to the induction of a number of
molecular changes on targets such as inflammation, adipokines,
mTOR11,12 and in the insulin-like growth factor (IGF-1R) pathway.30,37-39 Longo et al. have implied that short-term starvation,
or 48 h fasting (comparable to ADF), reduces IGF-1 levels by
70%, reduces glucose by 60% and increases IGFBP-1 11-fold.2
Previous studies have suggested that fasting induces several
metabolic changes; the major change being a shift to alternative nutrient sources and the reduction of growth factors such
as IGF-1.33,40,41
Our cDNA array analysis confirmed the importance of the
IGF-1R pathway in our model. Components of this pathway play
an important role in carcinogenesis, and elevation of pathway
components are prognostic for poor outcomes.37,42-44 Consistent
with that notion, downregulation of the IGF-1R signaling cascade leads to widespread apoptosis of cancer cells through the
PI3K/AKT pathway.45-48 In addition, it is also known that breast
tumors often express higher IGF-1 levels than normal breast tissues counterparts.34,49,50 Genotoxic therapies for breast cancer,
including radiation, are reported to decrease components of the
IGF-1R signaling pathway.35,36,51,52 Our results at the molecular
level demonstrate that various components of the IGF-1R pathway are downregulated with CR and RT used separately and are
further decreased by the combination of treatments. This suggests that this pathway might be a driving force in the anti-proliferative effect noted.
Our data suggests that nutrient restriction could be used in
combination with radiation therapy to confer a clinical benefit.
In fact, many novel therapeutic agents for cancer treatment target
molecules known to also be targets of CR, such as IGF1-R, the
PI3K/Akt pathway, mTOR and AMP-K.2,9,10,39,45,46,53 However,
while clinical studies to test these new drugs seem promising,
further studies may be limited by overlapping toxicity profiles of
the agents targeted at members of those pathways being used.54
Although CR has never been used as a treatment in oncologic
clinical trials,15 CR is being successfully implemented with diligent dietary counseling and behavior modification for other diseases in trials throughout the country.44,47,55,56 CR may be an ideal
complementary treatment modality for cancer, because it might
alter many molecular targets concurrently, and it is free of adverse
effects associated with multiple targeted agents.
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Mice and tumor cell injections. Eighty female Balb/c mice were
obtained from NCI Frederick at 6–8 wk of age and treated on
a NCI Animal Care and Use Committee approved protocol. At
14-wk-old, 20 mice were implanted with 67NR tumor cells (triple-negative locally advanced cells) to determine efficacy of the
treatment intervention (gift from Dr Fred Miller, Prentis Cancer
Research Center, Karmanos Cancer Institute). Sixty mice were
then implanted with 4T1 tumor cells, which are highly metastatic and randomized to a treatment arm (gift from Dr Patricia
Steeg, NCI). All cells were cultured in DMEM supplemented
with 10% FBS and pen/strep.
For implantation, mice were anesthetized, shaved, and a small
incision (~0.5 cm) was made through the skin just anterior to the
rear leg in order to visualize the #4 mammary fat pad, so that
tumors could be created in situ. Five × 104 4T1 cells in 50 μL of
sterile PBS were injected into the fat pad and the site closed with a
staple. Tumors were measured three times per week using manual
calipers, and their volumes were determined by the formula: 1/2
length × width2. Mice were euthanized when the tumor reached
2,000 mm3 or earlier if required by humane endpoints.
67NR pilot intervention. A pilot trial was first performed to
determine if tumor regression in a locally aggressive triple-negative cell line could be noted with a dietary modification. To do
this, after implanting 67NR cells and waiting for palpable primary tumors with an average size of 60 mm3 to develop, mice
were placed in four treatment cohorts of five mice each. The
conditions for the cohorts included (1) mice given ad libitum
(AL) feeding; (2) mice treated with radiation (IR) to the primary
tumor; (3) mice given alternate day feeding (ADF) and (4) mice
treated with IR to the primary tumor and given ADF.
Average daily food intake per animal was determined for all
groups by weighing food 2–3 times per week. Intake baseline was
established at least 2 wk prior to implantation and/or altering
feeding protocol. All animals had unrestricted access to water
regardless of feeding protocol. Ad libitum fed (AL): AL animals
were given unrestricted access to standard NIH31 mouse diet for
the duration of the experiment. Alternate day feeding (ADF):
The dietary intervention of ADF is noted in the literature to be
equivalent to a global reduction of 30% calories. Therefore, for
this pilot intervention, animals were fasted and fed in alternating 24 h cycles starting when tumors became palpable around
1 wk after implant. During the fed state, mice were given ad
libitum access to NIH31 mouse diet. Ionizing radiation (IR):
Mammary fat pad tumors in the IR groups were irradiated when
the tumors were palpable with an average size of 100 mm3. Mice
were sedated, placed into a restraint jig with shielding to isolate
the tumor, and the tumor with margin was treated with a 6 Gy
dose for tumors generated from the 67NR cells using a Pantak
H-320 (320 kV) Precision X-Ray.
4T1 tumor intervention. Since benefit was noted with a pilot
trial of a locally aggressive cancer, a larger study was undertaken
to look at the efficacy of dietary intervention in the 4T1 model,
which is also a triple-negative cell line, but is highly metastatic.
We chose to evaluate radiation in conjunction with two different
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dietary interventions including ADF and caloric restriction, instituting a 30% reduction in calories to determine if both regimens
would have equivalent efficacy as previously reported. Therefore,
6 cohorts of 10 mice were evaluated in this portion of the study:
(1) AL feeding; (2) mice treated with (IR) to the primary tumor;
(3) mice given ADF; (4) caloric restriction (CR) or a 30% reduction in their daily intake; (5) mice treated with IR to the primary tumor and given ADF and (6) mice treated with IR to the
primary tumor while on a CR diet. Caloric restriction (CR): At
10-wk-old, each animal was singly housed, and baseline average
daily food intake of NIH31 mouse diet was calculated per individual over 2 wk. Starting 2 d after tumor implant, each animal
was fed once per day a weighed portion equivalent to 90% of its
individual average daily intake. Over an 18 d period, animals
were stepped down in 5% increments every 4–5 d, ensuring
weight loss was stabilized before each step until the animals were
calorically restricted to 70% of baseline. IR: As described above
12 d after implant, however, tumors generated from the 4T1 cells
were treated to 8 Gy using a Pantak H-320 (320 kV) Precision
X-Ray.
Clonogenic survival curves. To determine an equivalent dose
of radiation to treat mice implanted with two different cell types,
4T1 or 67NR cells were trypsinized and plated in 6-well plates at
the appropriate densities and then incubated for 6–8 h at 37°C.
Cells were then irradiated with a dose of 0, 2, 4, 6 or 8 Gy. The
plates were then incubated for 10 d and colonies were stained
with crystal violet. Colonies of 50 or more cells were counted,
and the fraction of surviving cells at each dose was calculated. A
dose of radiation was chosen to achieve a 90% cell kill in vitro.
This tuned out to be 6 Gy for 67NR cells and 8 Gy for 4T1 cells
as denoted in Figure S1.
RNA isolation and RT-PCR. Tumors were grossly dissected
and immediately stabilized by placement in RNAlater (Ambion)
per manufacturer’s instructions. Tissue was placed in TRIzol
reagent (Invitrogen) with lysing matrix D (MP Biomedicals)
and homogenized using manufacturer’s suggested settings for a
FastPrep-24 machine (MP Biomedicals). Following lysis, extraction was performed using a standard phenol-chloroform method.
Following extraction, 1 μl of 20 mg/ml glycogen (Fermentas) and
1.5 volumes of 100% ethanol was added to each sample. Total
RNA was then purified using RNeasy Mini columns (Qiagen)
using standard manufacturer’s protocol. RNA concentration was
determined and integrity was confirmed by viewing 18S and 28S
by denaturing agarose gel electrophoresis. mRNA expression for
IGF-1R, IRS-1, PIk3ca, mTOR, were assessed using the high
capacity cDNA reverse transcription kit (ABI) as per manufacturer’s instructions. RT-PCR reactions were performed using 20
ng of cDNA.
cDNA microarrays. RNA from primary tumors treated with
AL, CR, IR and CR + IR were labeled with Cy3-dUTP and compared with the reference RNA (Stratagene Universal Reference),
which was labeled with Cy5-dUTP. The method was previously
described by Khan et al.57 Microarray slides were obtained from
the Radiation Oncology Sciences Program Microarray Lab at
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the National Institutes of Health.58 Slides were 8 k human slides
printed on site using a Named Genes clone set from Research
Genetics, spotted onto poly-l-lysine coated slides using an
OmniGrid arrayer (GeneMachines). Hybridization and washing
were done as previously described and slides were then scanned
at 10 microns intervals using a Genepix® 4000 scanner (Axon
Instruments), and images and data were stored in a database
(mAdb) maintained by the Center for Information Technology,
National Institutes of Health.59 The microarray data have been
deposited in National Center for Biotechnology Information
Gene Expression Omnibus.60
Data analysis. Data was extracted into two categories using
the mAdb system: “all genes” and “outliers.” “All genes” were
extracted excluding spots flagged as Bad/Not found, and spots
with target diameters less than 50 μm or greater than 300 μm.
Only spots with signal-to-background ratios of > 2, a minimum
background corrected signal of 250 counts and 80% of pixels
in the spots with intensity greater than a SD plus background
were used excluding spots flagged as Bad/Not found. Local
Mean Across Element Signal Intensity (LOESS) was applied
to dye-normalization. Ratio data were analyzed by LIMMA
statistics to obtain significant genes with selection criteria p
≤ 0.01, Bonferroni correction by using R version 2.11.1 and
BioConductor package limma version 3.4.3. To identify biological pathways, including miRNA which altered by IR or/and
70% calorie restriction, pathway analysis was conducted using
GO-Elite and GenMAPP-CS.
Tissue staining and scoring. Formalin-fixed, paraffinembedded tissue sections were cut at 6 μm and deparaffinized by
standard techniques. Antigen retrieval was performed by heating
the sections in 10 mmol/L citrate buffer pH 6.0 for 50 min with
the use of a pressure cooker. A rabbit monoclonal antibody for
Ki-67 at 1:600 dilution (AbCam; catalog no. ab16667) for 60
min at room temperature. The immune complexes were visualized with Mouse ABC (Vector Laboratories, Inc) and the chromogenic substrate Dako Liquid DAB_Substrate-Chromogen
Solution (Dako North America, Inc; catalog no. K3468; diaminobenzidine tetrahydrochloride) for 3 min. Ki-67 labeling index
was determined by counting ≥ 500 nuclei in areas of the section
with the highest labeling rates and was considered high when ≥
10% of tumor cells were stained.61 The scoring was performed
by an experienced staff pathologist and was also interpreted with
the Aperio Image analysis system in order to obtain the number
and percentage of positive cells in each tumor.
Statistical analysis. Statisitical significance between tumor
growth curves was calculated as previously described.62 Briefly,
tumor growth data were fit using an exponential growth equation; the tumor growth time (days) for control animals was calculated and then subtracted from all treated groups. SDs were
derived and used to calculate the Student’s t-test and p values for
the differences between the various groups. Comparisons comparing statisitical significance for RT-PCR anaylsis was made by
the two-tailed Student’s t-test. A difference between groups of p
< 0.05 was considered significant.
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